ReviewClinical ophthalmology (Auckland, N.Z.)2023
Emerging Treatment Options for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration.
Review in Clinical ophthalmology (Auckland, N.Z.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 54 citations in OpenAlex.
- The Biochemical and Genetic Architecture of Geographic Atrophy: The Role of the FHL-1/CFH Axis and the Paradigm of RNA Interference Therapeutics.Biomedicines · 2026Review
- Tropomyosin-Related Kinase Receptor Type B Agonism in Geographic Atrophy-The Translational Challenges from Preclinical Data to a First-in-Human Trial.Ophthalmology science · 2026Article
- Signals of Drug-Related Retinal Fibrosis: Findings From a 20-Year Disproportionality Analysis of Global Spontaneous Reports.Translational vision science & technology · 2026Article
- Non-exudative macular neovascularization: a 3-year follow-up study assessing the progression for exudative or atrophic stages.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Observational
- Complement regulatory proteins are associated with progression rate of geographic atrophy secondary to age-related macular degeneration.Immunity & ageing : I & A · 2026Article
- Association between Baseline Subfoveal Choroidal Thickness and Anatomical and Functional Outcomes in Geographic Atrophy.Ophthalmology science · 2026Article
- Association between systemic complement levels and choroidal thickness in advanced non-neovascular age-related macular degeneration.Scientific reports · 2025Article
- Patient-reported visual difficulties associated with geographic atrophy from age-related macular degeneration.International ophthalmology · 2025Article
- Applications of Modern Cell Therapies: The Latest Data in Ophthalmology.Life (Basel, Switzerland) · 2025Review
- Geographic atrophy in Asia.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025Review
- Cytokines in age-related eye diseases: pathogenesis and potential targets for innovative therapies.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Enhanced retinal pigment epithelial cells as a delivery vehicle for retinal disease.Molecular therapy. Methods & clinical development · 2025Article
- Animal models for the evaluation of retinal stem cell therapies.Progress in retinal and eye research · 2025Review
- Ophthalmologists' awareness of geographic atrophy: An Italian survey including 365 participants.European journal of ophthalmology · 2025Article
- Predict and Protect: Evaluating the Double-Layer Sign in Age-Related Macular Degeneration.Ophthalmology and therapy · 2024Article
- Measuring Geographic Atrophy Area Using Column-Based Machine Learning Software on Spectral-Domain Optical Coherence Tomography versus Fundus Auto Fluorescence.Bioengineering (Basel, Switzerland) · 2024Article
- Retinoic acid related orphan receptor α is a genetic modifier that rescues retinal degeneration in a mouse model of Stargardt disease and Dry AMD.Gene therapy · 2024Article
- The Complement System as a Therapeutic Target in Retinal Disease.Medicina (Kaunas, Lithuania) · 2024Review
- Complement regulation in the eye: implications for age-related macular degeneration.The Journal of clinical investigation · 2024Review
- The identification of signature genes and their relationship with immune cell infiltration in age-related macular degeneration.Molecular biology reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Age-related macular degeneration (AMD) is characterized as a chronic, multifactorial disease and is the leading cause of irreversible blindness. Advanced AMD is classified as neovascular (wet) AMD and non-neovascular (dry) AMD. Dry AMD can progress to a more advanced form that manifests as geographic atrophy (GA), which significantly threatens vision, leading to progressive and irreversible loss of visual function. There are currently no approved therapeutics commercially available for GA patients. However, data from various clinical trials have demonstrated favorable results with significant reduction in GA lesion growth. This review furthers the understanding of the pathophysiology of GA, as well as current clinical trial data on investigational therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.